Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). Am J Cardiol (2009) 0.91

How to revascularize patients with diabetes mellitus: bypass or stents and drugs? Clin Res Cardiol (2006) 0.87

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag (2007) 0.83

Cardiac complications in type 2 diabetic patients with mild anginal symptoms and documented reversible myocardial perfusion defects: Results of the MERIDIAN trial. Neth Heart J (2006) 0.80

Use of metformin in diseases of aging. Curr Diab Rep (2014) 0.77

Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res (2009) 0.76

Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag (2007) 0.76

Multi-vessel coronary disease and percutaneous coronary intervention. Heart (2004) 0.75

Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial. J Am Heart Assoc (2017) 0.75

[Revascularization of coronary artery disease in diabetes mellitus]. Wien Med Wochenschr (2010) 0.75

Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation (2002) 2.34

Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25

Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation (2004) 2.00

Testing potential interference with RFID usage in the patient care environment. Biomed Instrum Technol (2008) 1.21

Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry. Am Heart J (2003) 1.19

Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol (2002) 1.15

Modeling and risk prediction in the current era of interventional cardiology: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circulation (2003) 1.08

Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2002) 1.03

What constitutes optimal surgical revascularization? Answers from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol (2002) 0.97

Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J (2002) 0.93

The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. Am Heart J (2006) 0.86

Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology (2008) 0.84

Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions <or=40%, 41% to 49%, and >or=50% having percutaneous coronary revascularization. Am J Cardiol (2003) 0.82

Marked improvements in outcomes of contemporary percutaneous coronary intervention in patients with diabetes mellitus. J Interv Cardiol (2006) 0.81

Post-transplantation growth among pediatric recipients of liver transplantation. Pediatr Transplant (2005) 0.78

Importance of the postdischarge interval in assessing major adverse clinical event rates following percutaneous coronary intervention. Am J Cardiol (2005) 0.77

Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry. Am Heart J (2005) 0.77

The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. J Thorac Cardiovasc Surg (2007) 0.76

Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation (2002) 0.76

A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation (2003) 0.75

Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord (2005) 0.75

In memoriam: Burton E. Sobel a tribute from family, friends and colleagues October 21, 1937 - May 3, 2013. Exp Biol Med (Maywood) (2013) 0.75

Effects of heart failure and diabetes mellitus on long-term mortality after coronary revascularization (from the BARI Trial). Am J Cardiol (2007) 0.75

The role of PCI and CABG in the management of coronary artery disease in patients with diabetes. Curr Diab Rep (2002) 0.75